Claims for Patent: 6,153,595

Summary for Patent: 6,153,595

Title:	Composition and method for treatment of CMV infections
Abstract:	This invention concerns compositions and methods for the treatment of CMV infections. Antisense oligonucleotides are provided which are effective antiviral agents. In preferred embodiments, the oligonucleotides contain at least one 2\'-methoxyethoxy modification and may be chimeric oligonucleotides.
Inventor(s):	Draper; Kenneth G. (Boulder, CO), Kisner; Daniel L. (Cardiff, CA), Anderson; Kevin P. (Carlsbad, CA), Chapman; Sharon (Lake Toxaway, NC)
Assignee:	Isis Pharmaceuticals Inc. (Carlsbad, CA)
Application Number:	08/838,715
Patent Claims:	1. An antisense oligonucleotide which is targeted to a nucleic acid encoding IE1, IE2 or DNA polymerase of human cytomegalovirus, has at least one 2'-O-CH.sub.2 CH.sub.2 --O--CH.sub.3 sugar modification, and is capable of inhibiting cytomegalovirus replication. 2. An oligonucleotide of claim 1 having SEQ ID NO: 22. 3. An antisense oligonucleotide which is targeted to a nucleic acid encoding IE1, IE2 or DNA polymerase of a human cytomegalovirus and is capable of inhibiting cytomegalovirus replication. 4. The oligonucleotide of claim 3 which is targeted to least a portion of the mRNA cap site, the AUG region, the conserved amino acid region, or the CMV insertion regions between bases 608-697 or 1109-1159 of the DNA polymerase gene. 5. The oligonucleotide of claim 3 which is targeted to at least a portion of the mRNA cap site, the AUG region or an intron/exon junction region of the IE1 gene. 6. The oligonucleotide of claim 3 which is targeted to at least a portion of the AUG/CAP site, the AUG region, an IE2 specific intron/exon junction region, or a nuclear location signal region of the IE2 gene. 7. The oligonucleotide of claim 3 which comprises SEQ ID NO: 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 or 90. 8. The oligonucleotide of claim 3 which has at least one backbone modification. 9. The oligonucleotide of claim 8 wherein the backbone modification is a phosphorothioate modification. 10. The oligonucleotide of claim 3 which has at least one 2' sugar modification. 11. The oligonucleotide of claim 10 wherein the modification is a 2'-O-alkyl, 2'-O-alkyl-O-alkyl or 2'-fluoro modification. 12. The oligonucleotide of claim 11 wherein the 2'-O-alkyl-O-alkyl modification is a 2'-O--CH.sub.2 CH.sub.2 --O--CH.sub.3 modification. 13. The oligonucleotide of claim 10 which is a chimeric oligonucleotide having at least 4 contiguous deoxynucleotides. 14. A pharmaceutical composition comprising an oligonucleotide of claim 1, claim 2 or claim 3. 15. A method of treating a patient suspected of having cytomegalovirus retinitis comprising administering to said patient a pharmaceutical composition comprising an effective amount of an antisense oligonucleotide which is targeted to a nucleic acid encoding IE1, IE2 or DNA polymerase of human cytomegalovirus and which is capable of inhibiting cytomegalovirus replication. 16. A method of treating a patient suspected of having cytomegalovirus retinitis comprising administering intravitreally to said patient a pharmaceutical composition comprising an effective amount of an antisense oligonucleotide targeted to a nucleic acid encoding IE1, IE2 or DNA polymerase of human cytomegalovirus. 17. The method of claim 16 wherein the pharmaceutical composition is administered by intravitreal injection. 18. The oligonucleotide of claim 8 wherein the backbone modification is a peptide nucleic acid modification. 19. The oligonucleotide of claim 18 which comprises at least a 10-base portion of SEQ ID NO: 22. 20. A phosphorothioate oligonucleotide having SEQ ID NO: 22 wherein each of nucleotides 1-7, counting from the 5' end of the oligonucleotide, has a 2'-O--CH.sub.2 CH.sub.2 --O--CH.sub.3 sugar modification, nucleotides 8-14 are 2'-deoxynucleotides, each of nucleotides 15-20 has a 2'-O--CH.sub.2 CH.sub.2 --O--CH.sub.3 sugar modification, and nucleotide 21 may be either a 2'-deoxynucleotide or may have a 2'-O--CH.sub.2 CH.sub.2 --O--CH, sugar modification, wherein every cytidine nucleotide in the oligonucleotide is a 5-methylcytidine. 21. A method of inhibiting cytomegalovirus retinitis in a human comprising administering to said human a pharmaceutical composition comprising an effective amount of the oligonucleotide of claim 20.

Details for Patent 6,153,595

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2010-08-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2010-08-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2010-08-16